In clinical studies, the ligand trap (dalantercept) (Jimeno et al. 2016) and the monoclonal antibody PF-03446962 of ACVRL1 have demonstrated desirable anti-tumour efficacy (Goff et al. 2016; Simonelli et al. 2016). This evidence concerns the gene ACVRL1 and neoplasm.